Canada House Wellness Group Inc. (CSE: CHV) (“
Canada
House” or the “
Company”), a fully
integrated medical cannabis company, announced today the
appointment of two new members of their senior management team, Dr.
Lew Pliamm as Medical Director and Liana Del Medico as Director
Communications and Investor Relations effective immediately.
The Medical Director is a strategic medical
advisor across all Canada House divisions. Dr. Lew Pliamm has
practiced Family Medicine for over 25 years in Toronto and is the
Lead Physician and Medical Director for the Polyclinic Family and
Specialty Medicine Facility as well as the Polyclinic Family Health
Group. Dr. Pliamm is also the Principal Investigator and
Medical Director of Canadian Phase Onward Inc., a clinical research
organization where he has worked for 20 years as a principal
investigator on numerous clinical trials for both the
pharmaceutical industry and academic institutions. Dr. Pliamm has
spoken for several organizations at an international level. In
addition to his various clinical leadership roles, Dr. Pliamm has
become a recognized expert in medically related real estate,
specializing in the development and leasing of medical buildings
which will support Canada House Clinic’s “clinic-in-clinic"
model.
“We are thrilled to bring Dr. Pliamm on board.
His experience in family practice and pharmaceutical industry
research can support all of our divisions,” said Chris
Churchill-Smith, CEO, Canada House. “Dr. Pliamm’s hire
demonstrates our commitment to leadership in cannabinoid therapy
and the continued development of leading medical cannabis
products.”
“I am very excited to be joining Canada House,”
added Dr. Pliamm. “The company is committed to patient care,
which is demonstrated by its support in clinics, the strength of
the leadership team, and Canada House’s ability, along with its
licensed producer, to deliver high quality medical cannabis.”
Mrs. Del Medico will work with the executive
team and lead all strategic communications and investor relations
activity across Canada House. She has worked in Corporate
Communications for over 20 years in various industries including
cannabis, pharmaceuticals, and consumer goods. She has an extensive
background in media, physician, investor, and consumer
communications, organizational change, and mergers and
acquisitions. Mrs. Del Medico also brings vast experience working
with various organizations in highly regulated environments.
“Finding a leading communications professional
with experience in highly regulated environments, specifically
pharmaceutical and cannabis, was important for the management team
at Canada House,” said Michael Orrbrooke, Chief Revenue Officer,
Canada House. “Liana comes with a wealth of experience dealing with
media, consumers, investors and regulators. We are thrilled to have
her onboard.”
About Canada House Wellness Group Inc.
Canada House Wellness Group Inc. is the parent
company of Abba Medix Corp., a Licensed Producer in Pickering,
Ontario that produces high quality medical grade cannabis; Canada
House Clinics Inc., with clinics across the country that work
directly with primary care teams to provide specialized cannabinoid
therapy services to patients suffering from complex medical
conditions; and Knalysis Technologies, a provider of fully
customizable, cloud-based software that links physician, provider,
and patient to data that supports treatment with medical
cannabis.
Canada House Wellness Group’s goal is to become
the leading cultivator of premium craft cannabis and provider of
cannabinoid therapy, targeting the medical cannabis markets
globally.
For more information please visit www.canadahouse.ca.
For further information, please
contact:
Liana Del Medico, Director of Communications &
Investor Relations Canada House Wellness Group
Inc.289-980-3584 liana.delmedico@canadahouse.ca
Cautionary Statement Regarding
Forward-Looking Information. This press release contains
forward-looking statements, including statements that relate to,
among other things, the Company’s clinic, production and technology
businesses, its future plans, the Company’s markets, objectives,
goals, strategies, intentions, beliefs, expectations and estimates,
and can generally be identified by the use of words such as “may”,
“will”, “could”, “should”, “would”, “likely”, “possible”, “expect”,
“intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective”
and “continue” (or the negative thereof) and words and expressions
of similar import. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, such statements involve risks and uncertainties, and
undue reliance should not be placed on such statements. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Material assumptions used to develop forward-looking information in
this news release include, among other things, the regulations
related to cannabis use under the Access to Cannabis for Medical
Purposes Regulations and the act respecting cannabis and to amend
the Controlled Drugs and Substances Act, the Criminal Code and
other Acts, passed by the Canadian Federal government, making
cannabis legal for recreational use by October 17, 2018; Company
liquidity and capital resources, including the availability of
additional capital resources to fund its activities; level of
competition; the ability to adapt products and services to the
changing market; the ability to attract and retain key executives;
and the ability to execute strategic plans. Additional information
about material factors that could cause actual results to differ
materially from expectations and about material factors or
assumptions applied in making forward-looking statements may be
found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as
in other public disclosure documents filed with Canadian securities
regulatory authorities. The Company does not undertake any
obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a
result of new information, future events or otherwise, except as
required by law.
Neither the CSE nor its Regulation Services
Provider (as that term is defined in the policies of the CSE)
accepts responsibility for the adequacy or accuracy of this
release.
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From May 2024 to Jun 2024
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From Jun 2023 to Jun 2024